Wart injections: vitamin D3 versus acyclovir
Intralesional Therapies For Cutaneous Viral Warts: A Comparative Analysis Of Vitamin D3 And Acyclovir
This test will try injecting either vitamin D3 or acyclovir into skin warts to see which better clears warts in people aged 12 and older.
Quick facts
| Phase | Phase 4 |
|---|---|
| Study type | Interventional |
| Enrollment | 40 (estimated) |
| Ages | 12 Years and up |
| Sex | All |
| Sponsor | Riphah International University Academic / other |
| Locations | 2 sites (Rawalpindi, Punjab Province and 1 other locations) |
| Trial ID | NCT07448844 on ClinicalTrials.gov |
What this trial studies
People with common, plantar, flat, or periungual warts will be assigned to receive intralesional injections of either acyclovir or vitamin D3, with 20 participants in each group. Injections are given every two weeks for up to four sessions, with photographs and measurements of wart size and number taken at each visit. The primary outcome is complete clearance of warts by week 8, and participants are followed for up to three months to monitor recurrence and side effects. Safety and local adverse reactions will be recorded and compared between the two groups.
Who should consider this trial
Good fit: People aged 12 years and older with clinically diagnosed common, plantar, flat, or periungual warts who are not pregnant, not immunocompromised, and have not had topical or destructive wart treatment in the prior three months.
Not a fit: Pregnant or lactating people, immunocompromised individuals, those with infected warts, or anyone with known hypersensitivity to vitamin D3 or acyclovir are excluded and would not be expected to benefit from participating.
Why it matters
Potential benefit: If one injection treatment proves more effective and well tolerated, it could provide a simple clinic-based option to clear warts faster and reduce recurrence.
How similar studies have performed: Intralesional vitamin D3 has shown positive results in prior small studies for wart clearance, while intralesional acyclovir is less well studied and represents a relatively novel approach in this setting.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Patients aged 12 years and above with clinically diagnosed cutaneous warts * Common, plantar, flat, or periungual warts * Both treatment-naïve patients and those with recalcitrant warts Exclusion Criteria: * Pregnant or lactating women * Immunocompromised patients * Individuals with history of hypersensitivity to vitamin D3 or acyclovir * Individuals receiving systemic immunosuppressive or antiviral therapy * Patients with secondary infection at injection site * Patients who had received any topical or destructive treatment for wart in previous three months
Where this trial is running
Rawalpindi, Punjab Province and 1 other locations
- Railway General Hospital, Railway Carriage Factory Rd, Railway Scheme 7, Rawalpindi — Rawalpindi, Punjab Province, Pakistan (Recruiting)
- Riphah International Hospital, Islamabad Expy, Sector A DHA Phase 5, Islamabad — Islamabad, Pakistan (Recruiting)
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.